We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Glucosamine and Chondroitin Effects (GLANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01682694
Recruitment Status : Completed
First Posted : September 11, 2012
Last Update Posted : May 28, 2014
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center

September 4, 2012
September 11, 2012
May 28, 2014
September 2012
August 2013   (Final data collection date for primary outcome measure)
hsCRP [ Time Frame: 1 year ]
hsCRP is a biomarker of systemic inflammation
Same as current
Complete list of historical versions of study NCT01682694 on ClinicalTrials.gov Archive Site
untargeted (exploratory) serum metabolomics (differences in small molecule abundance ratios) [ Time Frame: 1 year ]
The mechanisms of action of glucosamine and chondroitin are currently unknown. Untargeted metabolomic assays of serum will be undertaken for exploratory analyses of potential effects of glucosamine and chondroitin. Significant differences in abundance ratios of small molecules between the intervention and placebo will be reported.
Same as current
Not Provided
Not Provided
Glucosamine and Chondroitin Effects
Glucosamine and Chondroitin Effects
A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.
Use of glucosamine and chondroitin have been associated with reduced cancer and overall mortality. The aim of this study is to determine whether a common starting dose of glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic inflammation as reflected by a reduction in high sensitivity C-reactive protein.
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Dietary Supplement: Glucosamine and Chondroitin
    Glucosamine (1500 mg) and Chondroitin (1200 mg)
    Other Name: Nutramax
  • Dietary Supplement: placebo
  • Experimental: Glucosamine and Chondroitin
    Glucosamine and Chondroitin
    Intervention: Dietary Supplement: Glucosamine and Chondroitin
  • Placebo Comparator: Placebo
    Inactive ingredients
    Intervention: Dietary Supplement: placebo
Navarro SL, White E, Kantor ED, Zhang Y, Rho J, Song X, Milne GL, Lampe PD, Lampe JW. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015 Feb 26;10(2):e0117534. doi: 10.1371/journal.pone.0117534. eCollection 2015.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2013
August 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy
  • Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)
  • Non-smoking men and women
  • Aged 20-55y

Exclusion Criteria:

  • Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases)
  • Pregnancy or lactation
  • Currently on a weight-loss diet
  • BMI (body mass index) < 25 or > 30
  • Alcohol intake of greater than 2 drinks/day
  • Current use of prescription or over-the-counter medications, (Excluding oral contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more than 2 days per week
  • Abnormal renal, liver or metabolic test
  • Inability to swallow pills
  • Known allergy to shellfish
  • Not willing to take pills made from shellfish or animal sources
  • Intention to relocate out of study area within next 4 months
Sexes Eligible for Study: All
20 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
Not Provided
Not Provided
Fred Hutchinson Cancer Research Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP